InterMune (ITMN +5%) rallies after Brean Murray calls it a top 2012 pick, citing a low valuation...
InterMune (ITMN +5%) rallies after Brean Murray calls it a top 2012 pick, citing a low valuation and strong German demand for InterMune's Esbriet lung disease drug. Brean's call is more than offsetting a PT cut from Goldman (Neutral), which thinks uncertainty over future Esbriet pricing "creates an overhang that is likely to persist through the middle of 2012."
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs